Key result
Cardiac myosin inhibitors represent a novel, disease-specific pharmacological therapy that effectively reduces left ventricular outflow tract gradients and improves symptoms in patients with obstructive hypertrophic cardiomyopathy.
Why the study?
A therapeutic gap has existed between medical therapy for milder symptoms and septal reduction therapies in obstructive hypertrophic cardiomyopathy, which cardiac myosin inhibitors may fill.
Do cardiac myosin inhibitors improve symptoms and echocardiographic parameters in adults with hypertrophic cardiomyopathy?
Do cardiac myosin inhibitors improve symptoms and echocardiographic parameters in adults with hypertrophic cardiomyopathy?
Cardiac myosin inhibitors represent a novel, targeted pharmacological therapy that effectively reduces LVOT gradients and improves symptoms in patients with obstructive hypertrophic cardiomyopathy.
May support myosin inhibitors for HCM symptom relief; leaves open need for randomized outcome trials.
Hypertrophic cardiomyopathy (HCM) affects as many as 1 in 200 people in the adult population globally. Patients may present with exertional dyspnea, presyncope or syncope, atrial and ventricular arrhythmias, heart failure, and even sudden cardiac death. Current guideline-based therapy involves medical therapy for treatment of symptoms in milder forms of the disease and surgical or catheter-based septal reduction therapies in obstructive HCM. Until recently, there has existed a gap between these two approaches that is now being filled by a new class of drugs, cardiac myosin inhibitors, which directly target the underlying disease process in HCM. Current investigations examine the effects of two cardiac myosin inhibitors on reported symptoms, echocardiographic evidence of disease, and the associated need for septal reduction. This paper reviews the contemporary evidence for the use of cardiac myosin inhibitors in HCM in adults and highlights future directions for this exciting field of cardiovascular medicine.
No takes yet. Share an insight, caveat, or question.
Kalinski et al. (2024) conducted a review in Hypertrophic cardiomyopathy. Cardiac myosin inhibitors (mavacamten, aficamten) was evaluated. Cardiac myosin inhibitors represent a novel, disease-specific pharmacological therapy that effectively reduces left ventricular outflow tract gradients and improves symptoms in patients with obstructive hypertrophic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: